64B Stock Overview
PhenomeX Inc. operates as a functional cell biology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PhenomeX Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$0.93 |
| 52 Week Low | US$0.84 |
| Beta | 0.94 |
| 11 Month Change | 4.78% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 64B | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0.02% | -6.1% | -1.3% |
| 1Y | n/a | 2.0% | 7.4% |
Return vs Industry: Insufficient data to determine how 64B performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how 64B performed against the German Market.
Price Volatility
| 64B volatility | |
|---|---|
| 64B Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 64B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 64B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 285 | Siddhartha Kadia | phenomex.com |
PhenomeX Inc. operates as a functional cell biology company. The company enables scientists to reveal insights on cell function and obtain behavior of each cell. Its suite of tools and services offer unparalleled resolution and speed, accelerating the insights for advancing discoveries that can profoundly improve the prevention and treatment of disease.
PhenomeX Inc. Fundamentals Summary
| 64B fundamental statistics | |
|---|---|
| Market cap | €95.00m |
| Earnings (TTM) | -€118.74m |
| Revenue (TTM) | €68.48m |
1.4x
P/S Ratio-0.8x
P/E RatioIs 64B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 64B income statement (TTM) | |
|---|---|
| Revenue | US$71.82m |
| Cost of Revenue | US$25.32m |
| Gross Profit | US$46.50m |
| Other Expenses | US$171.03m |
| Earnings | -US$124.53m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | 64.75% |
| Net Profit Margin | -173.40% |
| Debt/Equity Ratio | 0% |
How did 64B perform over the long term?
See historical performance and comparison